EGFR-induced lncRNA promotes drug resistance in non-small cell lung cancer via phospho-TRIM28-mediated DNA damage repair.

Publication information:

Saxena, T. et al. EGFR-induced lncRNA promotes drug resistance in non-small cell lung cancer via phospho-TRIM28-mediated DNA damage repair. Proceedings of the National Academy of Sciences of the United States of America 122, e2415389122 (2025).

Abstract

Long noncoding RNAs (lncRNAs) play numerous roles in cellular biology and alterations in lncRNA expression profiles have been implicated in a variety of cancers. Here, we identify and characterize a lncRNA, TRIM28 Interacting DNA damage repair Enhancing Noncoding Transcript (), whose expression is induced upon epithelial growth factor receptor (EGFR) activation, and which exerts pro-oncogenic functions in EGFR-driven non-small cell lung cancer. Knocking down leads to decreased tumor-cell proliferation in both in vitro and in vivo model systems and induces sensitization to chemotherapeutic drugs. Using ChIRP-MS analysis we identified TRIM28 as a protein interactor of . promotes phosphorylation of TRIM28 and knocking down leads to accumulation of DNA damage in cancer cells via decreased TRIM28 phosphorylation. Altogether, our results reveal a molecular pathway in which regulates TRIM28 phosphorylation to promote tumor cell growth and drug resistance. Our findings suggest that can be developed as a biomarker or therapeutic target for mutant non-small cell lung cancer.